Prion Epitope Peptides for Targeted PrPSc Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for managing prion diseases, such as BSE and CWD, face challenges in developing effective vaccines due to self-tolerance issues and the need for conformation-specific targeting of PrPSc, with existing approaches often requiring harsh adjuvants and risking adverse immune responses.
Innovation Solution
Development of peptides comprising prion disease-specific epitopes from the YML region and rigid loop, expanded to include B cell epitopes, which induce robust PrPSc-specific immune responses, reducing the risk of adverse effects and enhancing immunogenicity through carrier molecules like RTX toxins or lyssavirus G proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing vaccine approaches are used to induce immune responses against PrPSc, then immunogenicity is improved, but self-tolerance issues and adverse immune responses worsen
Solution Approach 1:
The patent divides the PrPSc protein into specific conformational epitopes (YYR, YML, RL) that are only exposed in the misfolded pathogenic form. By segmenting the antigen into these specific regions, the vaccine induces immunity against PrPSc without triggering broad immune responses against normal PrPC, thereby reducing adverse effects while maintaining immunogenicity.
Solution Approach 2:
The invention targets specific local regions (epitopes) of the PrP protein that are conformationally exposed only in PrPSc. These localized epitopes (YYR at residues 128-130, YML at residues 130-132, RL at residues 149-156) have distinct properties that allow selective immune recognition of the pathogenic form without cross-reactivity with normal protein, resolving the contradiction between immunogenicity and safety.
2Reliability
If harsh adjuvants are used to overcome self-tolerance, then immune response strength is improved, but safety and adverse effects worsen
Solution Approach 1:
The patent extracts and eliminates the need for harsh adjuvants by focusing on conformational epitopes that are inherently immunogenic when properly presented. By taking out the problematic adjuvant component and relying instead on the intrinsic immunogenicity of the PrPSc-specific epitopes (particularly when presented on appropriate carriers), the invention achieves strong immune responses without compromising safety.
Solution Approach 2:
The invention uses carrier molecules as intermediaries to present the PrPSc epitopes to the immune system in a safe and effective manner. These carriers facilitate antigen presentation and immune activation without requiring harsh adjuvants, thereby mediating between the antigen and the immune system to achieve both strength and safety.
3Reliability
If conventional management tools are used to control prion transmission, then disease spread is reduced, but complete elimination of threat is prevented
Solution Approach 1:
The patent applies preliminary action by providing prophylactic vaccination before prion infection occurs. The vaccine pre-activates the immune system with PrPSc-specific antibodies, creating protective immunity in advance. This preliminary immune preparation enables the system to neutralize prions upon exposure, preventing infection before it can establish, thereby moving from reactive control to proactive prevention.
Solution Approach 2:
The invention implements preliminary anti-action by generating PrPSc-specific antibodies through vaccination that can preemptively neutralize infectious prions. These pre-formed antibodies bind to and neutralize PrPSc in the environment or at the site of potential entry, preventing the conversion of PrPC to PrPSc and blocking transmission before the disease process can begin.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides induce specific antibody responses that effectively target PrPSc, potentially breaking the transmission cycle of prion diseases, while minimizing adverse immune reactions and improving vaccine efficacy and safety.
Implementation Method 1
The peptides induce specific antibody responses that effectively target PrPSc
Data Source
AI summary
Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.